PMID- 15298149
OWN - NLM
STAT- MEDLINE
DCOM- 20040819
LR  - 20180908
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 121 Suppl
DP  - 2004 Jun
TI  - HER-2/neu evaluation in breast cancer are we there yet?
PG  - S33-49
AB  - The HER-2/neu oncogene is located on chromosome 17q and encodes a transmembrane 
      glycoprotein with intracellular tyrosine kinase activity. Several studies have 
      shown an association of HER-2 gene amplification or protein overexpression with 
      prognosis and predictor of therapeutic response. Most important, the presence of 
      amplification or overexpression is the basis of eligibility for trastuzumab 
      therapy. However, there are several methods of determining HER-2 status, each 
      measuring a different aspect such as DNA content, gene copy number, protein 
      expression, expression of RNA, and circulating HER-2 extracellular domain 
      protein. There is no consensus with regard to the optimal test for HER-2 
      assessment. This review examines the various methods used in an attempt to define 
      the most accurate and reliable test. The most widely used assays are 
      immunohistochemical analysis and fluorescence in situ hybridization (FISH), which 
      measure protein expression and gene amplification, respectively. Based on current 
      data, FISH is the most accurate and reproducible test with a better correlation 
      with prognosis and response to therapy.
FAU - Winston, Janet S
AU  - Winston JS
AD  - Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
FAU - Ramanaryanan, Jeyanthi
AU  - Ramanaryanan J
FAU - Levine, Ellis
AU  - Levine E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Algorithms
MH  - Breast Neoplasms/*chemistry/therapy
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis
RF  - 113
EDAT- 2004/08/10 05:00
MHDA- 2004/08/20 05:00
CRDT- 2004/08/10 05:00
PHST- 2004/08/10 05:00 [pubmed]
PHST- 2004/08/20 05:00 [medline]
PHST- 2004/08/10 05:00 [entrez]
AID - 10.1309/9UNL7UXPYO6CPWBQ [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2004 Jun;121 Suppl:S33-49. doi: 10.1309/9UNL7UXPYO6CPWBQ.